Skip to main content

AMIA’s goal is to improve the legislative and regulatory environment for health informatics research, practice and education through AMIA member expertise.  The primary pathway through which AMIA achieves this goal is by engaging Federal Agencies and Congress on public calls for input, such as Notices of Proposed Rulemakings (NPRMs) or Request for Information (RFIs).

Learn more about the comment process

AMIA responses are arranged by Federal Agency and Congressional Committee.

Showing 61 - 70 out of 85

AMIA Response Letter to Centers for Disease Control and Prevention (CDC)

September 7, 2012

Dear Dr. Buehler,

On behalf of AMIA (the American Medical Informatics Association), I am pleased to submit these comments in response to the above-referenced request for comments. AMIA thanks the Department of Health and Human Services and the Centers for Disease Control and Prevention (CDC) Public Health Surveillance and Informatics […]

AMIA Comments on PCORI Draft Research Agenda

March 16, 2012

AMIA and the NIWG submitted comments in response to the Patient-Centered Outcomes Research Institute’s (PCORI’s) request for comments about its draft National Priorities for Research and Research Agenda. PCORI was created to fund research that will give patients, caregivers, and clinicians more information to support health care decisions. AMIA thanked […]

AMIA Comments on NIST Usability Guidance

November 10, 2011

AMIA acknowledged NIST’s efforts to highlight the importance of usability testing for electronic health records (EHRs) through its issuance of the proposed guidance. AMIA expressed concerns about several aspects of the draft guidance including the following: a limited and narrow identification of EHR users; the need to consider more comprehensive […]

AMIA Submits Comments to HHS on the Common Rule

October 25, 2011

This week AMIA submitted comments to the Department of Health and Human Services (HHS) in response to the a request for comments regarding Human Subject Research Protections: Enhancing Protections for Research Subjects and Reducing Burden, Delay, and Ambiguity for Investigators (aka "the Common Rule").

Click below to read AMIA's comments.

AMIA Comments on FDA Mobile Medical Apps Draft Guidance

October 19, 2011

AMIA recently issued comments in response to a U.S. Food and Drug Administration (FDA) draft guidance on mobile medical applications. In the comments, AMIA president Ted Shortliffe noted, among other things, the need for additional clarification, definitions, terms, and terminology in the guidance. Click below to read AMIA's full comments.